Merck & Co., Inc. is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. The company has enhanced its portfolio and pipeline with external innovation and increased investment in new capital projects focused primarily on expanding manufacturing capacity across its key businesses. Merck's performance during 2019 demonstrates execution in both commercial and research operations driven by a focus on key growth drivers and innovative pipeline investment reinforcing the company's science-led strategy. The company is allocating resources to effectively support its commercial opportunities while making necessary investments to support long-term growth. Merck has prioritized business development aimed at enhancing its portfolio and strengthening its pipeline by executing several business development transactions. The company has also acquired Antelliq Group, a leader in digital animal identification, traceability, and monitoring solutions, augmenting its animal health business. The healthcare services segment provides services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. Merck's existing research pipeline programs will continue to be owned and developed within the company as planned. The company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, focusing on supplementing its internal research with a licensing and external alliance strategy. The company continues to pursue opportunities that have the potential to drive both near- and long-term growth, actively monitoring the landscape for growth opportunities that meet its strategic criteria. The company is also focused on digital transformation and enhancing its operational efficiency through technology deployment and strategic resource allocation. Merck's capital expenditures reflect investments in new capital projects aimed at increasing manufacturing capacity for its key products, with plans to invest more than $19 billion from 2019 to 2023. The company recognizes the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities to transform into a competitive force. The company has made significant investments in research and development, reflecting higher clinical development spending and increased investment in discovery research and early drug development. Merck's approach to investments has shifted toward venture capital investments in third parties as opposed to wholly-owned businesses. The company anticipates that actions taken to enhance its portfolio and pipeline will continue to yield performance gains and improve market responsiveness. The company's strategic management practices are designed to align its business strategy with market dynamics and consumer demands, ensuring operational flexibility and the ability to respond to competitive actions. The company continues to evaluate its global footprint and overall operating model, identifying additional actions to optimize its manufacturing and supply network. Merck's ongoing commitment to innovation and technology management is evident in its strategic resource allocation and capability enhancement initiatives, which are critical to achieving its organizational goals and maintaining its competitive positioning in the market.